Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent graft rejection and maintain the new kidney’s functionality, patients must commit to lifelong immunosuppressive therapy. Although these therapies offer significant benefits in preventing organ rejection, they pose several risks, including susceptibility to infections due to a weakened immune system, as well as long-term complications such as increased risk of certain cancers and cardiovascular events. Despite these challenges, immunosuppressive therapy remains a cornerstone of posttransplant care, requiring careful balancing of efficacy and safety. This report provides important insights into how these agents are used in the management of kidney transplant recipients and how clinical practices are evolving.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed kidney transplant recipients? What are the quarterly trends in prescribing among recently treated and newly diagnosed kidney transplant recipients?
- How have immunosuppressive therapies been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of kidney transplant recipients receive drug therapy within one year of diagnosis, and how quickly? What percentage of recipients progress to later lines of therapy within two years of diagnosis?
- What percentage of kidney transplant recipients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated recipients?
Market covered: United States
Key companies: Novartis, Astellas, Sebela, Genentech, Pfizer, Bristol-Myers Squibb, Sanofi, Amgen, Genzyme
Key drugs: Corticosteroids, calcineurin inhibitors (CNIs), antiproliferative agents, mTOR inhibitors, T-cell (lymphocyte) costimulation blocker, interleukin-2 receptor antagonists (IL-2 RA), lymphocyte-depleting agents
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
